BidaskClub upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research report sent to investors on Tuesday.
Separately, Zacks Investment Research downgraded Tocagen from a hold rating to a sell rating in a research note on Wednesday, September 27th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Tocagen currently has a consensus rating of Buy and a consensus price target of $23.67.
Shares of Tocagen (TOCA) traded up $0.31 during midday trading on Tuesday, reaching $13.94. The company’s stock had a trading volume of 195,600 shares, compared to its average volume of 182,853. Tocagen has a fifty-two week low of $8.60 and a fifty-two week high of $17.95. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07.
Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Tocagen by 52.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock worth $7,886,000 after purchasing an additional 218,100 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at about $366,000. Bank of New York Mellon Corp purchased a new stake in shares of Tocagen in the 2nd quarter valued at about $281,000. Vanguard Group Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at about $5,036,000. Finally, FMR LLC purchased a new stake in shares of Tocagen in the 2nd quarter valued at about $9,624,000. Institutional investors and hedge funds own 36.88% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Tocagen (TOCA) Lifted to Buy at BidaskClub” was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/24/tocagen-toca-lifted-to-buy-at-bidaskclub.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.